Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

(2016) Yoshiko Urata et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

(2016) Martin Schuler et al.   Journal of Thoracic Oncology

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer

(2016) Chee-Seng Tan et al.   LUNG CANCER

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

(2016) Keunchil Park et al.   JAMA Oncology

O1-10-2Combined analysis of two Phase II studies evaluating first-line erlotinib in NSCLC with EGFR mutation: JO22903/JO25567

(2015) Shinji Atagi et al.   ANNALS OF ONCOLOGY

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902

(2015) S. Sugawara et al.   ANNALS OF ONCOLOGY

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy

(2015) Shintaro Kanda et al.   LUNG CANCER

Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations

(2014) Toshihiko Iuchi et al.   International Journal of Clinical Oncology

Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy

(2014) Akimasa Sekine et al.   MEDICAL ONCOLOGY

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

(2014) Chiara D’Antonio et al.   Therapeutic Advances in Medical Oncology

Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer

(2013) Eunyoung Lee et al.   Journal of Thoracic Oncology

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

(2012) Yosuke Togashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection

(2011) Akito Hata et al.   LUNG CANCER

Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases

(2009) Yun Oh et al.   CANCER

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib

(2009) Tatsuya Katayama et al.   Journal of Thoracic Oncology